Sangodkar, Jaya

All roads lead to PP 2A: exploiting the therapeutic potential of this phosphatase

Sangodkar, J., Farrington, C. C., McClinch, K., Galsky, M. D., Kastrinsky, D. B., & Narla, G. (2016) · The FEBS Journal

Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling

Cited by 312

Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth

Sangodkar, J., Perl, A., Tohme, R., Kiselar, J., Kastrinsky, D. B., Zaware, N., Izadmehr, S., Mazhar, S., Wiredja, D. D., O’Connor, C. M., et al. (2017) · Journal of Clinical Investigation

Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling

Cited by 196

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells

Kauko, O., O’Connor, C. M., Kulesskiy, E., Sangodkar, J., Aakula, A., Izadmehr, S., Yetukuri, L., Yadav, B., Padzik, A., Laajala, T. D., et al. (2018) · Science Translational Medicine

Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling

Cited by 149

Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer

McClinch, K., Avelar, R. A., Callejas, D., Izadmehr, S., Wiredja, D., Perl, A., Sangodkar, J., Kastrinsky, D. B., Schlatzer, D., Cooper, M., et al. (2018) · Cancer Research

Prostate Cancer Treatment and ResearchPI3K/AKT/mTOR signaling in cancer

Cited by 78

Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors

O’Connor, C. M., Leonard, D., Wiredja, D., Avelar, R. A., Wang, Z., Schlatzer, D., Bryson, B., Tokala, E., Taylor, S. E., Upadhyay, A., et al. (2020) · Oncogene

Protein Tyrosine PhosphatasesMelanoma and MAPK Pathways

Cited by 48